This Presentation gives summarized overview of Gall Bladder Carcinoma especially the management as per latest National Comprehensive Cancer Network(NCCN) Guidelines version 2.2013
Colorectal cancer is most common GI cancer
The rectum is the most frequent site involved
Adenoma-carcinoma sequence: Arises from adenoma in stepwise progression
Gall bladder carcinoma seen in Indian popluation most common in women and presents at a very late stage .Survival is in months hence palliative treatment is being preferred .
Please find the power point on Carcinoma of rectum. I tried present it on understandable way and all the contents are reviewed by experts and from very reliable references.
A multidisciplinary approach that includes surgery, medical oncology, and radiation oncology is required for optimal treatment of patients with rectal cancer
Colorectal cancer is most common GI cancer
The rectum is the most frequent site involved
Adenoma-carcinoma sequence: Arises from adenoma in stepwise progression
Gall bladder carcinoma seen in Indian popluation most common in women and presents at a very late stage .Survival is in months hence palliative treatment is being preferred .
Please find the power point on Carcinoma of rectum. I tried present it on understandable way and all the contents are reviewed by experts and from very reliable references.
A multidisciplinary approach that includes surgery, medical oncology, and radiation oncology is required for optimal treatment of patients with rectal cancer
Experiential Learning through the lens of Communities of Practice (CoP) theoryJibran Mohsin
Individual Presentation on "Experiential Learning through the lens of Communities of Practice (CoP) theory"
Advanced Level Course on Teaching and Learning 1
Master of Health Professions Education
Department for Educational Development
The Aga Khan University
Tuesday, February 07, 2023
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomized, open-label, phase 3 trial
CURRICULUM ON RESIDENCY PROGRAM FOR FCPS MOLECULAR PATHOLOGYJibran Mohsin
CURRICULUM ON RESIDENCY PROGRAM FOR FCPS MOLECULAR PATHOLOGY (Advanced Level Course on Curriculum Development in Health Professions Education, Department for Educational Development, The Aga Khan University)
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
1. Gall Bladder Carcinoma
Muhammad Haris Aslam Janjua
Resident, Surgical Unit I
SIMS/Services Hospital, Lahore
2. Case Summary
• A 40 Year old female presented to OPD SHL on 11th Jan 14, with pain in upper
abdomen for 15 days which was acute in onset, progressive, continuous,
constricting, moderate to severe, radiating to back side, aggravated by fatty meals
and relieved temporarily by medications.
• No h/o fever, vomiting, constipation/diarrhea ,weight loss
• Unremarkable medical and surgical history
• On examination: RHC was tender with Murphy sign +ve. Rest of examination
unremarkable.
• USG showed gall stones with no edema and thick GB wall.
• Serum amylase levels were 26, lipase levels were 11 and total bilirubin was 0.4 .
TLC was 11.0
• Patient was admitted and managed on lines of acute cholecystitis
• During her stay in the ward departmental USG showed cholelithiasis and multiple
enlarged lymph nodes in porta hepatis and peripancreatic area . Patient was sent
on leave and advised follow up after CT scan and CA 19-9 report.
3. Case Summary
• CT scan(17th Jan 14) showed multiple enlarged lymph nodes in porta
hepatis and both para-aortic planes and pleuropericardial recess. CA19-9
level (24th Jan 2014)were 15.68 (normal range less than 37)
• Patient was re-evaulated and was discharged on conservative treatment
• Patient again presented in ER on 7th Feb 14, with pain RHC and was
readmitted for workup
• Serum amylase was 60, total bilirubin was 0.7 ,TLC 10.0
• Repeat USG showed Multiple Gallstones with soft tissue density mass.
However wall is not thick and no pericholecystic fluid. CHD dilated upto
6mm but distal CBD and intrahepatic duct was not dilated . Multiple
enlarged lymph nodes in para aortic, celiac, peri pancreatic and porta
hepatic regions with liver slightly coarse in echo texture.
• Laparatomy was done on 13th Feb 14 and intraoperatively gall bladder
mass was seen infiltrating the liver and GB biopsy was taken, which
showed Poorly Differenciated adenocarcinoma.
5. Relevant Anatomy
• Saccular structure located at the inferior surface of the
liver, at the division of the right and left lobes, just
below segments IV and V
• Composed of 4 areas: fundus, body, infundibulum, and
neck
• Approx. 7-10 cm long and about 2.5-3.5 cm wide
• Normally contains approx. 30-50 mL of fluid(max up to
300 mL)
6. Relevant Anatomy
Lymphatic Drainage
• Cystic Node
• pericholedochal nodes
• regional nodal basins (superior mesenteric,
retropancreatic, retroportal, and celiac)
• aortocaval nodes*( directly or indirectly)
*exposure of this region is a necessary step in the operative staging of gallbladder
cancer
7. Relevant Anatomy
Spread of GB cancer
• spreads via the lymphatic channels and venous
drainage
• Peritoneal metastasis common
• Due to adjacent location liver, bile duct, portal
vein, hepatic artery, duodenum, and transverse
colon involvement is common
8. Relevant Anatomy
Cystic Plate*
• It is reflection of the visceral peritoneum between the liver and the
gallbladder.
• Dissection between the gallbladder and the liver during
cholecystectomy divides the plane between the cystic plate and
the muscle layer of the gallbladder
*anatomic basis for the improved survival in patients undergoing liver
resection for T1b gallbladder cancer.
9. Introduction
• Gallbladder carcinoma was first described by Maximilian Stoll in
1777 and more than 200 years later it is still considered to be a
highly malignant disease with a poor survival rate
• G.B cancer is relatively uncommon but it is the 5th most common
GIT malignancy(worldwide)
• most frequent malignant tumor of the biliary tract
• 90 % Adenocarcinomas.
• Mucosal squamous metapalsia Squamous cell carcinoma
10. Introduction
Premalignant Lesions
• Adenomatous polyps
– Papillary adenomas grow as pedunculated, complex,
branching tumors projecting into the gallbladder lumen.
– Tubular adenomas arise as a flat, sessile neoplasm.
• Adenomyomatosis
– extensions of Rokitansky-Aschoff sinuses through the
muscular wall of the gallbladder
– USG reveals a thickened gallbladder wall with intramural
diverticula
– serial evaluation with USG is indicated to rule out
enlarging adenomatous polyps and gallbladder cancer
11. Epidemiology
• incidence of GC 1 to 23 per 100,000 worldwide
• over the last three decades there is decrease in incidence in
developed and increase in incidence in developing countries
• The highest incidence of gallbladder carcinoma is reported more
recently from the Indian-Subcontinent including India and Pakistan
(18-23/100,000) mirror image of worldwide distribution of gall
stones
• A relatively rare malignancy worldwide but is the second
commonest gastrointestinal cancer in Pakistani women
• Most common cause of gastrointestinal cancer related mortality in
females in subcontinent.[17,18]
12. Epidemiology
• Rise in incidence of GC from Northern India and Southern Pakistan
over the past two decades
• Frequency of gallbladder cancer in Pakistan varies between 6-7%.
[13-15]
• Highest incidence is found in Chelians, American Indian and in parts
of Northern India where it accounts for 9% of all biliary tract
diseases.
• Female to male ratio is 3:1
• Peak incidence is in 7th decade of life.[2]
13. Etiology/Pathophysiology
• Gallstones are present in 60-90 % of GB cancer cases (World wide)
.[3][12].
– a small proportion of patients (1-3%) with gall stones developed G.B cancer
[16,17]
– inverse relationship between the incidence of GC and rate of cholecystectomy
– In pakistan 98-100 % of cases of GC have gall stone[18][19]
• Risk factors include
– Chronic inflamation and infection.
– Porcelain Gallbladder
– Typhoid carrier
– Adenomatous polyp (size of the polyp is strongest predictor of malignant
transformation)[3]
– Advanced age(>55 yr)
– Multiparity(>5)
– Presence of gallstone larger than 1[17]-3[18]cm.
– Anomalous pancreatobiliary junction
– Drugs :OCP, methyldopa
14. – Occupational exposure to rubber,cigrette smoking
– Bile acid composition.
– Diet: low fibre, low calories. High fine CHO, low protein
• A 2008 study found evidence that excess body weight
in women, specifically a 5 kg/m 2increase in the body-mass
index, is strongly associated with an increased
risk of gallbladder cancer.[4]
• Numerous studies have investigated genetic
abnormalities in gallbladder cancer and have shown
that approximately 39-59% of gallbladder cancers are
associated with the K-ras mutation, while more than
90% of them are associated with a p53 mutation.[5]
15. Presentation
• Usually asymptomatic at the time of diagnosis
• Symptoms if present are similar to benign
diseases such as cholecystitis or biliary colic.
• Jaundice and anorexia are late features
• Palpable mass is a late sign[2]
• Given this presentation, less than 50% of
gallbladder cancers are diagnosed preoperatively.
Many are diagnosed incidentally in gallbladders
removed for biliary colic or cholecystitis.
16. Work Up
• Laboratory studies are generally nonspecific for gallbladder
cancer.
• In the later stages, liver function enzyme levels may be slightly
elevated. These levels are generally not elevated in stages I
and II.
• An elevated bilirubin or alkaline phosphate level generally
indicates advanced or obstructive disease.
Tumour Marker Sensitivity Specificity
CA 19-9 * 79.4 % 79.5%
CEA 50 % 93%
*Found in 80% of the cases
17. Imaging studies
• Ultrasonography is a very useful tool in the workup of
gallbladder cancer. Polypoid lesions need to be at least 5
mm in size to be detected by ultrasonography. Cholesterol
polyps (benign) generally appear as pedunculated lesions
attached to the gallbladder wall.
• Ultrasonographic findings that indicate possible malignancy
– a thick gallbladder wall,
– vascular polyp,
– a mass projecting into the lumen or invading the wall, multiple
masses or a fixed mass in the gallbladder,
– a porcelain gallbladder, and an extracholecystic mass. Invasion
of the liver can also be seen on ultrasonograms.
18. This image demonstrates heterogeneous
thickening of the gallbladder wall (arrows). The
diagnosis was primary papillary adenocarcinoma of
the gallbladder.
19. • Computed tomography (CT) scanning and magnetic resonance
imaging (MRI) are useful in evaluating the extent of invasion and
resectability of gall bladder tumors. CT scan results suggestive of
gallbladder cancer include asymmetrical wall thickening or
gallbladder mass with or without invasion into the liver.
• CT scanning of the chest, abdomen, and pelvis is a common staging
modality that can determine the presence of distant metastases
and give reliable information about involvement of other organs
and vascular structures.
• Positron emission tomography (PET) scanning has a sensitivity of
75% and a specificity of 88% in gallbladder cancer but is not used
routinely.
20. Partially calcified gallbladder (arrow). At
laparotomy and histology,
an infiltrating adenocarcinoma of the
gallbladder was confirmed.
CT scan showing squamous cell
carcinoma of gall bladder showing Liver
metastasis
21. Diagnostic procedures
• Percutaneous CT scan – guided biopsy is avoided in patients
considered resectable based on preoperative imaging. Because of
the substantial risk of peritoneal seeding, percutaneous biopsy and
diagnostic cholecystectomy are not necessary in the patient
suspected of having gallbladder cancer. In these patients,
exploration with curative intent is planned based on preoperative
imaging alone.
• Percutaneous CT scan – guided biopsy is a useful diagnostic tool in
patients who appear to have a nonresectable tumor. Tissue
diagnosis is necessary for palliative treatment.
• Endoscopic ultrasonography with fine-needle aspiration Biopsy
can be used to evaluate for peripancreatic and periportal
lymphadenopathy.
22. Staging
• The American Joint Committee on Cancer (AJCC) has designated staging by the TNM (primary t umor, regional
lymph n odes, distant m etastasis) classification as follows [6]
• TNM Definitions
Primary tumor (T)
• TX - Primary tumor cannot be assessed
• T0 - No evidence of primary tumor
• Tis - Carcinoma in situ
• T1 - Tumor invades lamina propria or muscle layer . T1a - Tumor invades lamina propria
• T1b - Tumor invades the muscularis
• T2 - Tumor invades the perimuscular connective tissue; no extension beyond the serosa or into the liver
• T3 - Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver and/or 1 other adjacent organ
or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts
• T4 - Tumor invades the main portal vein or hepatic artery or invades multiple extrahepatic organs or structures
Regional lymph nodes (N)
• NX - Regional lymph nodes cannot be assessed
• N0 - No regional lymph node metastasis
• N1 - Portal lymph node metastasis
• N2 - Distant lymph node metastasis such as periaortic, pericaval, superior mesenteric artery, or celiac artery
Distant metastasis (M)
• MX - Distant metastasis cannot be assessed
• M0 - No distant metastasis
• M1 - Distant metastasis
23. AJCC Stage Groupings
• Stage 0: Tis, N0, M0
• Stage I: T1 (a or b), N0, M0
• Stage II: T2, N0, M0
• Stage IIIA: T3, N0, M0
• Stage IIIB: T1 to T3, N1, M0
• Stage IVA: T4, N0 or N1, M0
• Stage IVB: Any T, N2, M0, OR Any T, any N, M1
24. In Our case......................
• T3 (liver involvement)
• N2 (para-aortic and celiac lymph node
involvement )
• M1(as paraaortic LN involvement is
considered sign of distant metastsis)
• i.e. Stage IVB
25. Non surgical Management
• Small gallbladder tumors are common and many can be safely followed
with serial ultrasonographic examination. It is generally thought that
polyps of less than 1 cm are safe to follow, although a study[7] has
recommended that polyps that are greater than or equal to 6 mm should
be considered for cholecystectomy.
• Chemotherapy is used in the adjuvant and palliative treatment of
gallbladder cancer. Phase II studies have shown that the use of single-agent
chemotherapy (with gemcitabine or 5-fluorouracil) in the palliative
setting can be beneficial.
• Combination chemotherapy also has been shown to be beneficial and is
usually based on gemcitabine, capecitabine, and 5-fluorouracil used in
combination with cis-platinum or oxaliplatinum. Fluoropyrimidine-based
chemoradiotherapy is commonly employed in the palliative and adjuvant
setting as well.
26. Surgical management
• Cholecystectomy recommended in
– polyps larger than 1 cm or with polyps in the setting of primary sclerosing
cholangitis
– porcelain gallbladder.[2]
• Diagnostic Laproscopy
– In order to exclude the presence of undetected intra-abdominal metastases
prior to curative laparotomy.
– Surgery is contraindicated in the presence of distant metastases.
• Exploratory Laparotomy
– The initial exploration focuses on the presence of metastatic disease that was
not detected by preoperative imaging and staging laparoscopy.(15%)
– In view of North american surgeons Biopsy-proven metastases in the celiac
nodes preclude resection.
– Aortocaval nodal metastases are considered distant metastatic disease.
27. STAGE TREATMENT
T1a Simple cholecystectomy
T1b or deeper Hepatic resection +
lymph node dissection
(portal , peripancreatic , and retroduodenal)+
Resection of liver segments
IVb and V +/-
extended liver resection
and/or bile duct resection
28. Intraoperative ultrasonography (IOUS)
• To evaluate the extent of involvement of the liver, as well as
the portal and intrahepatic vasculature.
• This information is especially useful when ligating the pedicle
to segment V and avoiding injury to the right anterior portal
pedicle or segment VIII pedicle. Extended right hepatectomy
may be necessary to achieve tumor clearance if the tumor
involves the right portal pedicles
29. A schematic drawing of the
extent of lymphadenectomy for
gallbladder cancer, especially
when the extrahepatic biliary
tree is resected.
Gallbladder tumors.
A schematic
drawing of the
extent of resection
of liver segments
IV-b and V for
gallbladder cancer.
30. • Surgical exploration
– will determine the need to resect other organs that may
be involved, such as the stomach, duodenum, and colon.
– It may be difficult to distinguish scar from malignancy. In
these cases, suspicious tissue should be treated as
malignancy in order to improve the chances of a margin-negative
resection.
– If tumor is suspected on the bile duct based on a previous
pathology report or operative exploration, the presence of
tumor on the right hepatic duct must be evaluated.
– Suspicion of tumorous involvement of the right hepatic
duct will require an extended right hepatectomy, excision
of the extrahepatic biliary tree, and Roux-en-Y
hepaticojejunostomy to the left hepatic duct.
• A recent study indicates that accurate staging requires
examination of at least 6 lymph nodes.
31. No standard adjuvant treatment protocol has been
defined for gall bladder cancer.
– A 2008 study found that only 20% of patients with gall
bladder cancer received adjuvant treatment.[9]
– In the report, no benefit from adjuvant therapy could
be demonstrated, but only a small number of patients
received this treatment.
– Generally, fluoropyrimidine-based chemoradiotherapy
or single-agent chemotherapy with fluoropyrimidines
or gemcitabine is used.[10]
– Because of the high cure rate with surgery alone for
T1N0 lesions, adjuvant therapy is not commonly
offered to these patients.
32.
33.
34.
35.
36.
37. Complications
• The overall complication and morbidity rate is
approximately 25%.
• Complications are similar to those experienced
with cholecystectomy and include infection,
hematoma, and bile leaks.
• Complication rates are higher in patients
undergoing more extensive resections.
• Liver failure can occur following extended
hepatectomy, especially if jaundice is present
preoperatively.
38. PROGNOSIS [5][11]
STAGE 5 YEAR SURVIVAL RATE
T1b 100% especially with hepatectomy
T2 38% to 77% after extended
cholecystectomy
III and IV 25 % with extended resection
Unresectabe disease < 5% ( 1 year survival rate)
Patients with unresectable disease have a median survival of 2-4 months
39. Follow Up
• There are no data to support aggressive
surveillance following resection of gall bladder
cancer, because treatment of recurrences is
not generally effective. However, many
clinicians and patients prefer follow-up
imaging every 6 months.
40. References
1. D'Hondt M, Lapointe R, Benamira Z, Pottel H, Plasse M, Letourneau R, et al. Carcinoma of the
gallbladder: Patterns of presentation, prognostic factors and survival rate. An 11-year single centre
experience. Eur J Surg Oncol. Jun 2013;39(6):548-53
2. Bailey and Love edition 26th page 1116
3. Robins and cotrans pathologic basis of disease 7th edition
4. [Best Evidence] Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a
systematic review and meta-analysis of prospective observational studies. Lancet. Feb 16
2008;371(9612):569-78.
5. Tumors of the gallbladder. In: Blumgart LH, ed. Surgery of the Liver, Biliary Tract, and Pancreas. 4th ed.
Philadelphia, Pa: Saunders Elsevier; 2007:764-81
6. American Joint Committee on Cancer. Gallbladder. In: AJCC Cancer Staging Manual. 6th ed. New York,
NY: Springer; 2002:139-44.
7. Zielinski MD, Atwell TD, Davis PW, et al. Comparison of surgically resected polypoid lesions of the
gallbladder to their pre-operative ultrasound characteristics. J Gastrointest Surg. Jan 2009;13(1):19-25.
8. [Best Evidence] Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a
systematic review and meta-analysis of prospective observational studies. Lancet. Feb 16
2008;371(9612):569-78.
9. Duffy A, Capanu M, Abou-Alfa GK, et al. Gallbladder cancer (GBC): 10-year experience at Memorial
Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. Dec 1 2008;98(7):485-9.
10. NCCN Clinical Practice Guidelines in Oncology™. Available at www.nccn.org.
11. Okada K, Kijima H, Imaizumi T, et al. Wall-invasion pattern correlates with survival of patients with
gallbladder adenocarcinoma. Anticancer Res. Feb 2009;29(2):685-91.
12. 10. Zarin M, Ahmed M, Gohar A, Waheed D, Khurram S, Aurangzeb M, et al. Incidence of Gall stones in
carcinoma gallbladder patients. Pak J Surg 2005;21(1):19-22.
41. 13. Hassan TJ, Zuberi SJ, Maqsood R. Carcinoma of gallbladder. J
Pak Med Assoc 1978;28:33-4.
14. Mubarik A, Ahmed M, Khan AH, Mansoor A. Carcinoma of
gallbladder - A study of 112 consecutive cases. Pak Armed Forces
Med J 1990;43:1-7.
15. Yaqin HU, Parmar BK. A comparative study of biliary tract disease
in Karachi (Pakistan) and Aylesbury (England). J Pak Med
Assoc 1976;26(8):162-4.
16. Mohandas KM, Patil PS: Cholecystectomy for asymptomatic
gallstones can reduce gall bladder cancer mortality in northern
Indian women. Indian J Gastroenterology 2006, 25:147-151.
17. John AP, Ashley R, Alan G: Primary carcinoma of the
gallbladder.HBP 1991, 4:277-289
18. Talat JH, Sarwar A J: Risk Factors for Gallbladder Cancer in Karachi.J
Ayub Med Coll Abbottabad 2003.
19. Bhurgri Y, Bhugri A, Hassan SH: Cancer Incidents in Karachi Pakistan:
First results from Karachi cancer registry. Int J Cancer 2000, 85:325-
9.